---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269469"
form_type: "8-K"
ticker: "CARL"
cik: "0001794546"
company_name: "CARLSMED, INC."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:55:03.487018+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Carlsmed Q3 revenue $13.1M (up 98% YoY); raises FY2025 guidance to $49M-$50M

## Summary
- Gross margin expanded to 75.9% from 72.8%; net loss of $8.5M vs $7.8M a year ago.
- Cash $115.5M; amended debt facility to $50M with extended maturity and interest-only period.
- CMS NTAP for cervical aprevo procedures effective Oct. 1, 2025; commercial launch expected early 2026.
- Lead time for aprevo interbody implants reduced to 8 business days from 10 in Q2 2025.
- Appointed Jennifer Kamocsay as Chief Legal Officer and Secretary.

## SEC filing metadata
- accession: 0001193125-25-269469
- form_type: 8-K
- ticker: CARL
- cik: 0001794546
- company_name: CARLSMED, INC.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1794546/000119312525269469/0001193125-25-269469-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1794546/000119312525269469/carl-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269469
- JSON: https://secwatch.observer/filing/0001193125-25-269469.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269469.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.